Working… Menu

A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00208455
Recruitment Status : Terminated (DePuy discontinued this product in 2013, the clinical program was reviewed and this Study was closed.)
First Posted : September 21, 2005
Last Update Posted : June 26, 2017
Information provided by (Responsible Party):
DePuy International

Brief Summary:
The purpose of this study is to monitor the performance of the DePuy PROXIMA™ hip in the treatment of patients with hip joint disease requiring a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments. A subset of patients will undergo scans to allow the bone mineral density of the bone surrounding the implant to be monitored

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Osteoarthritis Post-traumatic Arthritis Avascular Necrosis Traumatic Femoral Fractures Congenital Hip Dysplasia Device: DePuy Proxima™ Hip Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 184 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Uncontrolled, Multi-Centre, Prospective, Post Marketing Surveillance Study to Monitor the Long Term Survivorship of the DePuy PROXIMA™ Hip in Subjects Requiring a Total Hip Replacement
Study Start Date : February 2005
Actual Primary Completion Date : September 2012
Actual Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hip Replacement

Arm Intervention/treatment
DePuy Proxima™ Hip
A short, anatomic, cementless femoral component for use in total hip arthroplasty
Device: DePuy Proxima™ Hip
A short, anatomic, cementless femoral component for use in total hip arthroplasty

Primary Outcome Measures :
  1. Kaplan-Meier survivorship calculated at the five-year time-point [ Time Frame: 5 yrs ]

Secondary Outcome Measures :
  1. Annual Kaplan-Meier survivorship calculations [ Time Frame: Annually ]
  2. Harris Hip Score [ Time Frame: 6mths, 1yr, 2yrs, 5yrs, 7 yrs, 10yrs and 15 yrs post-surgery ]
  3. Radiographic analysis [ Time Frame: 6mths, 1yr, 2yrs, 5yrs, 7yrs, 10yrs and 15yrs post-surgery ]
  4. Oxford Hip score [ Time Frame: 6mths, and annually post-surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

i) Male or female subjects between 18 and 70 years of age.

ii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.

iii) Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and agree to return to the hospital for all the required post-operative follow-ups.

iv) Subjects who are scheduled to undergo a primary total hip replacement whom the surgeon considers to be suitable for the DePuy PROXIMA™ hip femoral prosthesis.

Exclusion Criteria:

i) Subjects who, in the opinion of the Investigator, have an existing condition/co-morbidity or infection that would compromise their long term participation and follow-up in this study.

ii) Women who are pregnant.

iii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.

iv) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s).

v) Subjects who are currently involved in any injury litigation claims.

vi) Subjects for whom the surgical procedure is a revision of a previous THR or hemi-arthroplasty, or who have previously undergone arthrodesis or osteotomy of the hip.

vii) Subjects undergoing a simultaneous bilateral hip operation.

viii) Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip is part of this clinical investigation.

ix) Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip was implanted less than six months previously or is not performing satisfactorily

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00208455

Layout table for location information
Asklepios Klinikum
Bad Abbach, Germany
Ospedale San Pietro
Rome, Italy
Arnau de Vilanova
Valencia, Spain
United Kingdom
North Bristol NHS Trust
Bristol, United Kingdom
Sponsors and Collaborators
DePuy International

Layout table for additonal information
Responsible Party: DePuy International Identifier: NCT00208455     History of Changes
Other Study ID Numbers: CT03/09
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: June 26, 2017
Last Verified: June 2017
Keywords provided by DePuy International:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hip Dislocation
Hip Dislocation, Congenital
Femoral Fractures
Joint Diseases
Musculoskeletal Diseases
Pathologic Processes
Fractures, Bone
Wounds and Injuries
Leg Injuries
Joint Dislocations
Hip Injuries
Musculoskeletal Abnormalities
Congenital Abnormalities